Status:

COMPLETED

Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing

Lead Sponsor:

Denver Health and Hospital Authority

Collaborating Sponsors:

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Conditions:

Alcohol Related Disorders

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The study objective was to determine if liver injury develops in alcoholic patients during or following 5 days of therapeutic acetaminophen dosing. Volunteers were recruited from two community detoxif...

Eligibility Criteria

Inclusion

  • 18 years and older
  • admitted to participating detox facility with a positive BAL at the time of admittance
  • signed a written informed consent

Exclusion

  • serum acetaminophen level greater than 20 mcg/ml
  • serum AST or ALT levels greater than 200 IU/L
  • INR greater than 1.5
  • if female, positive for beta-subunit of chorionic gonadotropin (beta-HCG)
  • clinically intoxicated, psychiatrically impaired or unable to give informed consent
  • known hypersensitivity to acetaminophen
  • history of ingesting more than four grams of APAP per day for any of the four days preceding study enrollment
  • currently enrolled in another trial or had been enrolled in another trial in the preceding three months.

Key Trial Info

Start Date :

November 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2005

Estimated Enrollment :

181 Patients enrolled

Trial Details

Trial ID

NCT00427206

Start Date

November 1 2004

End Date

December 1 2005

Last Update

February 9 2009

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Denver CARES

Denver, Colorado, United States, 80204

2

Centre for Addiction and Mental Health

Toronto, Ontario, Canada, M5S 2S1